Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
In the exploratory analyses of the phase III ASCEMBL trial, individuals with chronic myeloid leukaemia in chronic phase (CML-CP) who have failed ≥2 prior tyrosine kinase inhibitors (TKIs) continued to achieve deep responses with asciminib, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP).
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
04 Aug 2023Memories of childhood maltreatment affect mental health more than the abuse itself
Young adults with memories of childhood maltreatment have a greater number of depressive or anxiety episodes in adulthood vs those with official court records but not memories of such maltreatment, a large longitudinal study has found.
Memories of childhood maltreatment affect mental health more than the abuse itself
04 Aug 2023HDP exposure in gestation, maternal hypertension spell increased hypertension risk in offspring
Exposure to hypertensive disorders of pregnancy (HDP) in gestation and maternal hypertension both contribute to an elevated risk of chronic hypertension in offspring, as reported in a study.
HDP exposure in gestation, maternal hypertension spell increased hypertension risk in offspring
03 Aug 2023Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
03 Aug 2023Synbiotics help reduce weight in adults with overweight, obesity
Synbiotics V5 and V7 effectively reduce body weight in individuals with obesity or overweight undergoing lifestyle modification, as shown in a study.
Synbiotics help reduce weight in adults with overweight, obesity
03 Aug 2023Abrocitinib effectively controls AD regardless of dosing regimen
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.